NEW YORK, May 1, 2024 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for central nervous system disorders, today announced the initiation of patient dosing with GM-1020 in a Phase 2a study in Major Depressive Disorder (MDD) to assess safety, tolerability, and efficacy. GM-1020 is a novel, orally bioavailable NMDA receptor antagonist with reduced sedative and dissociative side effects. The study will include an initial placebo-controlled crossover phase followed by a 2-week multiple dose period.
Gilgamesh Pharma Awarded $14 Million National Institute on Drug Abuse Grant
NEW YORK, Sept. 21, 2023 /PRNewswire/ -- Gilgamesh Pharma, a cutting-edge clinical-stage biotechnology company proudly announces the successful completion of its Phase 1 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) trials for GM-1020, the only novel oral, small-molecule NMDA receptor channel blocker currently in clinical development. This next-generation therapy is poised to potentially transform the treatment landscape for major depression, bipolar disorder, obsessive-compulsive disorder (OCD), and other debilitating mental health conditions.